NEXTRACKER
14.3.2023 07:04:42 CET | Business Wire | Press release
Nextracker Inc. (NASDAQ: NXT) secured a new deal in Europe for its terrain-following solar tracker NX Horizon-XTR™ (XTR), demonstrating demand for tracking technology that enables solar developers to build on land with complex topography and unique environmental constraints. The German international solar developer, IbVogt, chose Nextracker’s XTR for the 150 MW Garnacha solar power plant in Spain. The project is backed by a 12-year power purchase agreement (PPA) with Google and is expected to begin production October of 2023. Leading the global market in solar trackers and optimization software, Nextracker’s advanced technology systems allow solar panels to follow the sun’s movement and maximize energy output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005879/en/
European Renewable Energy Developer IbVogt chooses Nextracker’s NX Horizon-XTR for its upcoming 150 MW project in Spain (Photo: Business Wire)
“Due to the local zero grading requirements on our project, we needed a solar tracker solution that would have minimal environmental impact and allow us to secure local permits,“ stated Patrick Zenker, Global Procurement Director of IbVogt. ” With a 10-gigawatt track record, NX Horizon-XTR gave us peace of mind and low risk."
“With gas price volatility, European leaders are looking for the lowest cost, most reliable form of energy, and that is utility scale solar power,” said Dan Shugar, Founder and CEO of Nextracker. “Europe’s exceptional environmental stewardship, unique cultural sites and challenging topography provide the perfect conditions for our terrain-following trackers that maximize energy output with a light-on-land footprint.”
Nextracker’s NX Horizon-XTR™ allows rows of solar panels to adjust to uneven terrain, following the natural curvature of the earth. Its terrain-following capabilities enable developers to work on challenging sites that would otherwise be infeasible. It also cuts costs by limiting grading work and associated delays, simplifying the permitting process, and reducing the need for soil-related maintenance.
Solar projects using NX Horizon-XTR have a lighter impact on the environment as they leave more soil intact, benefitting the local ecology and reducing risk of soil erosion. The projects also require less steel for extended pilings, lowering a project’s overall carbon footprint.
The Garnacha project expands Nextracker’s multi-gigawatt portfolio in Europe. The company has offices in Seville and Madrid, with dedicated employees working with customers across the continent with deep expertise to support the life cycle of every project.
“The Nextracker European team has achieved an important milestone of reaching over 3 GW of projects with major solar developers, utilities and European EPC companies for projects in Europe as well as Brazil, USA, Canada and Africa,” said Arturo Herrero, Nextracker SVP Europe.
Nextracker, a leading solar tracking company with 70 GW shipped globally to five continents, has deployed their terrain-following NX-Horizon XTR on close to 10 GW of utility-scale solar globally. Nextracker’s solar trackers increase energy production by 20-30% more than fixed-tilt applications that do not track the sun.
About Nextracker
Nextracker is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. Our products enable solar panels in utility-scale power plants to follow the sun’s movement across the sky and optimize plant performance. With more than 70 gigawatts shipped worldwide, Nextracker offers solar tracker technologies that optimize and increase energy production while reducing costs for significant plant ROI. For more information, please visit Nextracker.
Stay in touch with us: Twitter LinkedIn Instagram Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom